Ectonucleotidase

Ectonucleotidases are a diverse family of cell-surface enzymes that catalyze the hydrolysis of extracellular nucleotides, such as ATP, ADP, and NAD+, into their respective nucleosides like adenosine [1, 4]. This enzymatic cascade is a critical regulator of purinergic signaling, balancing the pro-inflammatory effects of extracellular ATP with the potent immunosuppressive actions of adenosine [2, 6]. In the tumor microenvironment, overexpressed ectonucleotidases like CD39 and CD73 facilitate immune evasion by depleting immunostimulatory ATP and accumulating adenosine, which inhibits T-cell and natural killer cell activity [5, 9]. Consequently, these enzymes have emerged as high-priority therapeutic targets in oncology, with several monoclonal antibodies and small-molecule inhibitors currently in clinical trials [3, 14]. Beyond cancer, ectonucleotidases play pivotal roles in managing vascular homeostasis, platelet aggregation, and chronic inflammation [8, 16]. Therapeutic modulation of these pathways aims to restore immune surveillance in tumors or dampen pathological inflammation in autoimmune and cardiovascular diseases [10, 11]. However, targeting these enzymes requires careful consideration of potential safety concerns, including altered hemostasis and the risk of systemic autoimmunity [10, 15].

Other names

Ecto-nucleotidaseEcto-ATPaseEcto-nucleoside triphosphate diphosphohydrolaseEcto-phosphodiesteraseSurface-located nucleotide metabolizing enzyme

Inhibition of extracellular nucleotide hydrolysis to modulate purinergic signaling and reduce immunosuppressive adenosine levels [3, 9, 14].